1. Scrip
  2. >>COVID-19

Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe

 
• By Jessica Merrill

Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.

Silhouette of reaching, giving a helping hand, hope and support each other over sunset background.
Sanofi will help in COVID-19 vaccine production • Source: Shutterstock

Having faced setbacks for its own COVID-19 vaccine, Sanofi is pitching in to help make a rival vaccine to aid in addressing the unprecedented demand for COVID-19 vaccines. The company said on 26 January that it will assist with the production of 100 million doses of the Pfizer Inc./BioNTech SE vaccine for the European market in 2021.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Data From China Bolster Summit/Akeso’s Case For Ivonescimab

 
• By Alaric DeArment

Results from the Phase III HARMONi-6 trial showed the PD-1/VEGF bispecific antibody beating out BeiGene’s Tevimbra in NSCLC.